Cargando…

Fenofibrate and Impaired Taste Perception in Type 2 Diabetes

Patient: Female, 65-year-old Final Diagnosis: Type 2 diabetes Symptoms: Loss of sweet taste Medication: Fenofibrate Clinical Procedure: Drug challenge/dechallenge/rechallenge Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual clinical course BACKGROUND: Although reduced sweet taste perception...

Descripción completa

Detalles Bibliográficos
Autor principal: Davis, Timothy M.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684425/
https://www.ncbi.nlm.nih.gov/pubmed/33214542
http://dx.doi.org/10.12659/AJCR.927647
_version_ 1783613012678017024
author Davis, Timothy M.E.
author_facet Davis, Timothy M.E.
author_sort Davis, Timothy M.E.
collection PubMed
description Patient: Female, 65-year-old Final Diagnosis: Type 2 diabetes Symptoms: Loss of sweet taste Medication: Fenofibrate Clinical Procedure: Drug challenge/dechallenge/rechallenge Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual clinical course BACKGROUND: Although reduced sweet taste perception has been found in studies of clofibrate in healthy volunteers, this phenomenon has not been reported for the chemically related and more widely used drug fenofibrate. CASE REPORT: A 65-year-old woman with insulin-treated type 2 diabetes was initiated on fenofibrate for worsening diabetic retinopathy. She subsequently developed a marked loss of sweet taste perception. After 3 months of fenofibrate, her glycemic control had improved and her insulin requirements had decreased, probably as a result of anorexia. Her renal function had also worsened. Dechallenge resulted in near normalization of sweet taste and restoration of her pretreatment renal function 2 weeks later. Rechallenge provoked recurrence of severely impaired sweet taste perception, which led to permanent discontinuation of fenofibrate. CONCLUSIONS: This case shows that altered sweet taste perception is a potential clinically significant adverse effect of fenofibrate therapy. There is increasing interest in the function of sweet taste receptors, which are recognized as having a broader role in cellular function and inflammation in tissues such as the kidney and retina that are relevant to type 2 diabetes and its complications.
format Online
Article
Text
id pubmed-7684425
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-76844252020-12-03 Fenofibrate and Impaired Taste Perception in Type 2 Diabetes Davis, Timothy M.E. Am J Case Rep Articles Patient: Female, 65-year-old Final Diagnosis: Type 2 diabetes Symptoms: Loss of sweet taste Medication: Fenofibrate Clinical Procedure: Drug challenge/dechallenge/rechallenge Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual clinical course BACKGROUND: Although reduced sweet taste perception has been found in studies of clofibrate in healthy volunteers, this phenomenon has not been reported for the chemically related and more widely used drug fenofibrate. CASE REPORT: A 65-year-old woman with insulin-treated type 2 diabetes was initiated on fenofibrate for worsening diabetic retinopathy. She subsequently developed a marked loss of sweet taste perception. After 3 months of fenofibrate, her glycemic control had improved and her insulin requirements had decreased, probably as a result of anorexia. Her renal function had also worsened. Dechallenge resulted in near normalization of sweet taste and restoration of her pretreatment renal function 2 weeks later. Rechallenge provoked recurrence of severely impaired sweet taste perception, which led to permanent discontinuation of fenofibrate. CONCLUSIONS: This case shows that altered sweet taste perception is a potential clinically significant adverse effect of fenofibrate therapy. There is increasing interest in the function of sweet taste receptors, which are recognized as having a broader role in cellular function and inflammation in tissues such as the kidney and retina that are relevant to type 2 diabetes and its complications. International Scientific Literature, Inc. 2020-11-20 /pmc/articles/PMC7684425/ /pubmed/33214542 http://dx.doi.org/10.12659/AJCR.927647 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Davis, Timothy M.E.
Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
title Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
title_full Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
title_fullStr Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
title_full_unstemmed Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
title_short Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
title_sort fenofibrate and impaired taste perception in type 2 diabetes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684425/
https://www.ncbi.nlm.nih.gov/pubmed/33214542
http://dx.doi.org/10.12659/AJCR.927647
work_keys_str_mv AT davistimothyme fenofibrateandimpairedtasteperceptionintype2diabetes